161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
Reports Second Quarter 2025 Financial Results and Business Highlights
Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
Material Contracts, Shareholder votes
Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
Annual Report to Security Holders
Denali Therapeutics Begins BLA Filing for Tividenofusp Alfa's Accelerated Approval
Reg. FD
Q2
Q1
Q3
FY 2023
S-3ASR
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence